Wedbush analyst Andreas Argyrides has once again assessed Regenxbio (NASDAQ:RGNX) with a Neutral rating and upholds a $21 price target. This confirmation reflects a careful approach in light of uncertainties in the company’s pipeline and the competitive market landscape. Andreas Argyrides, a respected analyst on Wall Street at Wedbush, specializes in the General sector and provides coverage on a range of stocks, including Regenxbio.
Date: February 28, 2024
RGNX Stock Shows Strong Performance with 9.16% Increase – February 28, 2024
On February 28, 2024, RGNX stock had a strong performance, closing at $20.02, which was a significant increase of $1.68 or 9.16% from the previous trading day. This positive price momentum is a good sign for investors, indicating that there is growing interest and confidence in the company’s prospects.
RGNX is currently trading in the middle of its 52-week range and above its 200-day simple moving average. This suggests that the stock has been relatively stable and is experiencing a positive trend in its price movement.
However, it is important to note that the stock dropped $0.63 in after-hours trading, which could indicate some profit-taking or a shift in sentiment among investors. It will be interesting to see how the stock performs in the coming days and whether it can maintain its upward momentum.
Overall, RGNX’s strong performance on February 28, 2024, is a positive sign for investors and could indicate that the company is on a path to continued growth and success.
Regenxbio Inc. (RGNX) Stock Performance Analysis: Mixed Results on February 28, 2024
On February 28, 2024, Regenxbio Inc. (RGNX) stock experienced mixed performances based on the financial data provided by CNN Money. The company reported a total revenue of $112.72 million for the past year, which represented a significant decrease of 76.03% compared to the previous year. However, there was a positive sign as the total revenue increased by 44.74% since the last quarter. In terms of net income, Regenxbio Inc. reported a loss of $280.32 million for the past year, indicating a decrease of 319.27% compared to the previous year. On a positive note, the net income improved by 14.14% since the last quarter. The earnings per share (EPS) for the company were reported at -$6.50 for the past year, showing a decrease of 323.14% compared to the previous year. However, the EPS increased by 14.96% since the last quarter. These financial results indicate a mixed performance for Regenxbio Inc. on February 28, 2024. Investors may need to closely monitor the company’s financial performance and future developments to make informed decisions regarding RGNX stock.
